Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trade Sales Trump IPOs, Even for Platforms

This article was originally published in Start Up

Executive Summary

Europe's summertime flurry of private biotech sell-offs points to growing pragmatism among management and VCs, and still-poor valuations on the public markets. Firms which haven't already considered the trade sale opportunity should do so--even early-stage, pre-product platform groups.

Related Content

Specialty Pharma: Tapping Japan
Pfizer Sets New Biotech M&A Record
Asset-Focused Funding
Reverse Mergers Gain Traction In Tough IPO Times
Few IPOs Fighting the Biotech Tide
UK Stem Cell IPOs Defy Odds
Stepping Out, Not Up: Better Returns for VCs Through M&A?
Validating Europe's De-Risked Approach
Theravance: Having Cake and Eating It
Sosei's Drug Re-Profiling Strategy: A Three-Way Street


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts